•The
set of new compositions that enhance the efficacy of mAb-based
treatment by modulating the population of target antigens
•It
consists
of pairing an established immunotherapeutic mAb
with a lipid-like nanoparticle delivery system that delivers antigen-encoding
mRNA
•In
vivo data demonstrates that this technology markedly enhances cancer survival
rates compared to standard mAb
treatment